Alector Inc is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative diseases... Show more
Alector, Inc. (ALEC) shares have traded within a wide band over the past year, ranging from a 52-week low near $1.09 to a high near $2.76. As of late October 2026, the stock closed around $2.10, reflecting a gain of roughly 7.7% over the trailing 30 days. The company carries a market capitalization in the range of roughly $300 million and a beta near 0.62, indicating lower day-to-day volatility relative to the broader market. Trading volume has been elevated around recent corporate announcements, underscoring heightened investor attention to pipeline and financing developments.
Alector is a clinical-stage biotechnology company pioneering an immuno-neurology approach to treating neurodegenerative diseases. Headquartered in South San Francisco, the company applies genetics, immunology, and neuroscience to develop therapies that aim to remove toxic proteins, replace missing proteins, and restore immune and nerve cell function. Its pipeline targets Alzheimer's disease, Parkinson's disease, frontotemporal dementia, and related conditions.
A central differentiator is the Alector Brain Carrier (ABC), a proprietary platform designed to shuttle therapeutics across the blood-brain barrier, a longstanding obstacle in neurological drug development. Alector's wholly owned programs include AL137, a brain-enabled anti-amyloid beta antibody, along with tau and alpha-synuclein siRNA candidates. The company also maintains a strategic collaboration with GlaxoSmithKline (GSK) focused on progranulin-elevating monoclonal antibodies, including latozinemab and nivisnebart.
The defining event of the period was Alector's announcement in early October 2026 of an exclusive global licensing agreement with Genentech, a member of the Roche Group, for AL050, a brain-penetrant engineered glucocerebrosidase (GCase) enzyme replacement therapy designed to address GCase deficiency in Parkinson's disease and other neurodegenerative conditions. Under the terms, Alector received a $100 million upfront payment and is eligible for up to $1.17 billion in development, regulatory, and commercial milestones, plus tiered royalties. The agreement extends the company's projected cash runway into 2029 while allowing Alector to retain full ownership of the ABC platform.
Shortly after, Alector priced an underwritten offering of 36.6 million shares at $2.05 per share, roughly a 7.3% premium to the prior close, generating about $75 million in gross proceeds. The financing drew participation from investors including TCGX, BVF Partners, ADAR1 Capital Management, and Deep Track Capital. Separately, the board approved a repricing of employee stock options to support retention. These moves followed an R&D webinar focused on the wholly owned pipeline, which contributed to a more constructive view of the platform's broader value.
Analyst responses were mixed. H.C. Wainwright lifted its price target to $8 from $5, describing Alector as a platform company, while Morgan Stanley (MS) raised its target to $3 from $2 but maintained an Underweight rating, framing the Genentech deal primarily as a balance-sheet and runway event.
Tickeron's Trending AI Robots page showcases a curated selection of AI-driven trading bots drawn from a broader library of hundreds of bots that trade thousands of tickers. Rather than displaying every strategy, the page highlights the top-performing and most relevant bots, helping users quickly identify approaches that align with different risk profiles. These bots vary in trading style, timeframe, and performance metrics, spanning swing trades, day trades, and longer-horizon strategies across multiple asset classes. For traders seeking data-driven, automated approaches to complement their own research, the Trending AI Robots section offers a practical starting point for exploring algorithmic strategies.
Looking ahead, several factors are likely to shape Alector's trajectory. Near-term attention centers on the company's next quarterly results, expected in early November 2026, which should provide updated cash, collaboration revenue, and operating-expense figures following the Genentech and Spur Therapeutics agreements. Investors will also monitor progress on AL137, including any multi-cohort clinical data in Alzheimer's disease, and the advancement of the tau and alpha-synuclein siRNA programs toward IND-enabling studies and filings.
Broader readouts, including the INFRONT-3 study of latozinemab in FTD-GRN under the GSK collaboration, remain relevant to sentiment around the progranulin franchise. As a clinical-stage company with no product revenue, Alector's outlook also depends on disciplined capital deployment, potential future partnerships, and the inherent binary risks of late-stage neurodegeneration trials. Macroeconomic conditions and sector-wide biotech financing sentiment may further influence valuation.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
The Stochastic Oscillator for ALEC moved out of overbought territory on November 12, 2026. This could be a bearish sign for the stock and investors may want to consider selling or taking a defensive position. A.I.dvisor looked at 64 similar instances where the indicator exited the overbought zone. In 58 of the 64 cases the stock moved lower. This puts the odds of a downward move at 90%.
The 10-day RSI Indicator for ALEC moved out of overbought territory on November 12, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 20 similar instances where the indicator moved out of overbought territory. In 17 of the 20 cases, the stock moved lower in the following days. This puts the odds of a move lower at 85%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ALEC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
ALEC broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for ALEC entered a downward trend on November 03, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Momentum Indicator moved above the 0 level on October 27, 2026. You may want to consider a long position or call options on ALEC as a result. In 74 of 98 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 76%.
The Moving Average Convergence Divergence (MACD) for ALEC just turned positive on October 27, 2026. Looking at past instances where ALEC's MACD turned positive, the stock continued to rise in 33 of 39 cases over the following month. The odds of a continued upward trend are 85%.
ALEC moved above its 50-day moving average on November 04, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for ALEC crossed bullishly above the 50-day moving average on November 04, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 79%.
Following a +6.91% 3-day Advance, the price is estimated to grow further. Considering data from situations where ALEC advanced for three days, in 218 of 260 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
The Tickeron Valuation Rating of 6 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-25.646) is normal, around the industry mean (3.498). P/E Ratio (-2.101) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.658) among similar stocks. P/S Ratio (15.060) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. ALEC’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 93 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ALEC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a developer of therapeutics for Alzheimer's disease and other neurodegenerative disorders
Industry Biotechnology